✦ LIBER ✦

Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group

✍ Scribed by Martha Q. Lacy; Susanna Jacobus; Emily A. Blood; Neil E. Kay; S. Vincent Rajkumar; Philip R. Greipp

Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 248 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2009.01.020

No coin nor oath required. For personal study only.

✦ Synopsis

The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks. The trial was modified due to toxicity after the first 16 patients. IL-12 was given 300 ng/kg subcutaneously twice weekly for 24 weeks. Of 48 eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed.

📜 SIMILAR VOLUMES

Phase II trial of taxol in salivary glan

Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group

✍ Jill Gilbert; Yi Li; Harlan A. Pinto; Timothy Jennings; Merrill S. Kies; Paula S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

## Background: Malignant tumors of the salivary glands make up approximately 5% of head and neck cancers. the eastern cooperative oncology group (ecog) initiated a phase ii evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies. ## Methods: Chemo-nai

Phase II trial of gemcitabine in patient

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797) : A trial of the Eastern Cooperative Oncology Group

✍ Scott Okuno; Louise M. Ryan; John H. Edmonson; Dennis A. Priebat; Ronald H. Blum 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Abstract ## BACKGROUND The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma. ## METHODS Twenty‐five patients with advanced sarcomas, who previously were untreated for metastatic disease, were treated on an Eastern Coo

Phase II study of α2 interferon in the t

Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders (E5487) : A trial of the Eastern Cooperative Oncology Group

✍ Arthur I. Radin; Haesook T. Kim; Barbara W. Grant; John M. Bennett; John M. Kirk 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

## Abstract ## BACKGROUND In vitro and clinical data suggest a therapeutic role for α2 interferon (IFN) in the treatment of the chronic myeloproliferative disorders. Accordingly, a multiinstitutional, Phase II trial of IFN in patients with agnogenic myeloid metaplasia (AMM), essential thrombocythe

An eastern cooperative oncology group ph

An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma

✍ Robert S. Witte; Paul Elson; Janardan Khandakar; Donald L. Trump 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 359 KB 👁 2 views

## Background. Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important. Because methotrexate has activity in advanced bladder cancer, this trial was initiated.

A Phase II trial of cisplatin plus WR-27

A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma : An Eastern Cooperative Oncology Group Study (E8188)

✍ William J. Gradishar; Patricia Stephenson; Donna J. Glover; Donna S. Neuberg; Me 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

Phase II trial of trimetrexate for patie

Phase II trial of trimetrexate for patients with advanced gastric carcinoma : An Eastern Cooperative Oncology Group Study (E1287)

✍ Ramesh K. Ramanathan; Stuart Lipsitz; Robert F. Asbury; Raman Qazi; Bernard R. G 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 2 views

## BACKGROUND. A Phase II study was conducted to evaluate the response, duration of response, and duration of survival of patients with measurable gastric carcinoma treated with trimetrexate (TMTX) who had not had prior chemotherapy. ## METHODS. Thirty-three patients with unresectable or metast